A NEW comparative study has found that cladribine provides greater protection against disability progression than sphingosine-1-phosphate receptor modulators in Treatment-Naive Relapsing-Remitting MS, while maintaining comparable relapse rates…
A NEW comparative study has found that cladribine provides greater protection against disability progression than sphingosine-1-phosphate receptor modulators in Treatment-Naive Relapsing-Remitting MS, while maintaining comparable relapse rates…